Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Safety and Innovation in Aesthetics: Neauvia North America Launches the First and Only FDA Class II Cleared Plasma Device in the U.S. Market

Neauvia North America has announced that the U.S. Food and Drug Administration (FDA) has given Class II clearance to Plasma IQ, an innovative, non-surgical solution that helps improve the appearance of aging skin in delicate areas of the face. The device utilizes precise plasma technology to give the skin a refreshed and renewed appearance.


News provided by

Neauvia North America

Mar 12, 2020, 07:00 ET

Share this article

Share toX

Share this article

Share toX

Vimeo
Vimeo

RALEIGH, N.C., March 12, 2020 /PRNewswire-PRWeb/ -- Safety and Innovation in Aesthetics: Neauvia North America Launches the First and Only FDA Class II Cleared Plasma Device in the U.S. Market
Neauvia North America has announced that the U.S. Food and Drug Administration (FDA) has given Class II clearance to Plasma IQ, an innovative, non-surgical solution that helps improve the appearance of aging skin in delicate areas of the face. The device utilizes precise plasma technology to give the skin a refreshed and renewed appearance.

"Neauvia knows plasma. We are the first and only company to work hand in hand with the FDA to bring Plasma IQ to the aesthetic marketplace for safe and effective use as a Class II device. As the only manufacturer and seller of aesthetic handheld plasma devices in the US, we are able to deliver a device designed for the exacting needs of medical professionals. Neauvia is known worldwide as experts in the research and development of plasma. I could not be happier to bring yet another great Neauvia produced device to the US market," said Sean Wilson, President and CEO of Neauvia North America.

Neauvia knows plasma. We are the first and only company to work hand in hand with the FDA to bring Plasma IQ to the aesthetic marketplace for safe and effective use as a Class II device.

Post this

Neauvia's Plasma IQ is important not only to those looking to rewind the signs of aging, but also to the aesthetic industry at large. Though plasma energy has been used for many years across different industries, its application in aesthetic medicine is still relatively new. In a rush to take advantage of the new market opportunity in aesthetics, we have seen other plasma rejuvenation devices come to market with incomplete training and minimal safety and technical support.

Neauvia wanted to find a way to introduce the remarkable benefits of this technology in the U.S. while upholding the stringent quality and patient safety standards the brand is known for globally. The Neauvia team worked hand in hand with the FDA towards the Class II designation with the aim of minimizing risk and improving outcomes for the patients seeking this kind of treatment. The Class II designation ensures that Plasma IQ can only be used by medically licensed and certified practitioners who have been trained by Neauvia.

Plasma IQ is supported by a comprehensive suite of training materials and the company's clinical education is handled in-house, ensuring practitioners are well-prepared to provide safe treatments with impressive results. Plasma IQ providers always have a direct line to Neauvia's in-house medically trained, experts as they learn about and begin to leverage the revolutionary energy-based technologies that the company is bringing to market.

Neauvia's device is the result of years of expertise in end-to-end device manufacturing. Plasma IQ is designed, manufactured and serviced in-house, a process intended to ensure it reliably and consistently performs to the exacting safety and performance standards the company has set forth.

Plasma IQ ionizes the gas particles in the air, creating an arc between the device tip and the skin resulting in micro-injuries that trigger the body's natural healing response. Precise technology and careful technique limit damage to the surrounding area, helping to reduce downtime, improve healing and minimize the risk and severity of side effects.

The device is the second energy-based rejuvenation device in Neauvia North America's product portfolio, which emphasizes a holistic approach to beauty and aging by working synergistically and safely with the body's natural processes. The first device, Zaffiro, combines hydro-exfoliation and thermo-lifting to treat skin laxity and dullness in a wide range of treatment areas across the face and body.

Globally, Neauvia offers an extensive portfolio of products including hyaluronic acid dermal fillers, energy-based devices and clinical-grade skincare. Neauvia remains committed to providing innovative, safe and effective solutions for providers and their patients.

Plasma IQ is FDA cleared to be used in the removal and destruction of skin lesions and the coagulation of tissue. The most common side effects are swelling, tenderness, scabbing, and redness. Plasma IQ is Rx only and should only be used by medically licensed and certified practitioners. For full product and safety information, visit https://neauvia-us.com/plasma-iq/.

For more information on Neauvia North America, visit https://neauvia-us.com/.

SOURCE Neauvia North America

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.